August 25, 2022 -- Gensaic is collaborating with Ovid Therapeutics to develop up to three genetic medicines for central nervous system (CNS) disorders using its proprietary phage-derived particle (PDP) platform.
Ovid invested a total of $5 million in convertible preferred stock in Gensaic, and Gensaic will retain full rights to its technology. Ovid will have commercial rights to license and develop any resulting phage-derived gene therapies that emerge from the partnership. In addition, Ovid retains rights to invest in future rounds, the firms said.
The PDP platform can cross the blood-brain barrier and offers a tissue-specific delivery of large genetic cargos (> 20kb). PDPs originate from the microbiome and could translate into an immune-privileged and redosable gene delivery platform. The particles can be administered in various ways -- intravenously, orally, inhaled, or intrathecally -- and could be used for numerous genetic diseases. However, the current areas of focus are muscle, respiratory, and CNS.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
